2076975 2077203
최종편집 2024-03-29 06:02 (금)
Chong Kun Dang • Dong-A ST improve performance with $10 billion drugs in half-year
상태바
Chong Kun Dang • Dong-A ST improve performance with $10 billion drugs in half-year
  • Heokgi Lee, Newsmp
  • 승인 2020.08.04 16:40
  • 댓글 0
이 기사를 공유합니다

Chong Kun Dang made $10 billion performance in every 10 products
Dong-A ST’s top drugs increased by 6.4%p

Chong Kun Dang and Dong-A ST improved performance with their main products in the first half-year of last year.

Both pharmaceutical companies overcame the COVID-19 crisis by growing their $10 billion drugs.

According to a recent report, Chong Kun Dang made its half-year sales over $600 billion, with a growth rate of 20% in the first half of last year.

▲ Chong Kun Dang and Dong-A ST improved performance with their main products in the first half-year of last year.
▲ Chong Kun Dang and Dong-A ST improved performance with their main products in the first half-year of last year.

In particular, major drugs recorded $10 billion in performance during this period. The top product, Januvia family exceeded $70 billion, and Atozet rose to $30 billion with a growth of 24.0%.

Gliatirin also achieved $30 billion with a growth of 6.0%, and K-CAB and Prevenar expanded their sales to $28 billion with 200~300% growth.

Dilatrend also increased its sales to $24.9 billion, and Prolia doubled its sales to $23.8 billion.

In addition, existing drugs such as Lipilou and Imotun showed their sales growth of around $19 billion.

Although Vytorin, which had $10.6 billion in sales in the first of last year, was pushed back to $9.2 billion, all other 10 products met a significant improvement compared to the same period of last year.

As a result, the combined sales of the top 10 products also surged 32.9% year-on-year to $276 billion, and the proportion of the top 10 products in Chong Kun Dang increased by 4.0% to 45.4% resulting in $606 billion sales. 

Dong-A ST struggled somewhat in the aftermath of the suspension of sales in the second quarter, but the pre-order effect in the first quarter resulted in a fine performance for the half-year.

The performance of the main items improved considerably compared to the same period of last year.

Don-A ST announces that the number of drugs that achieved more than $10 billion in the first half has risen from three last year to eight this year.

Growtropin, which has become a major product, rose 30.2% year-on-year, resulting in $15.1 billion in sales while Motilitone and Opalmon grew by 9% and 3.9%.

Stillen’s 36.6% growth reached $12.7 billion, followed by Gaster $12.1 billion with 137.7% growth, Suganon $11.7 billion with a doubled growth (112.7%), Plavitor $11.5 billion with 16.2% growth, and Jublia $10.7 billion with 27.4% growth.  

With their performance, the combined sales of the top 10 drugs jumped 29.1% year-on-year to $113.6 billion, and their proportion increased by 6.4% to 36.3% in Dong-A ST’s $312.8 sales. 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.